Navigation Links
Bayer's Xarelto® (rivaroxaban) Becomes First Fixed Dose Once-Daily Anticoagulant Tablet Approved in the UK for Stroke Prevention in non-valvular Atrial Fibrillation; and the First Single Drug Regimen for Deep Vein Thrombosis
Date:12/19/2011

p>].

The majority of patients suffering from a venous blood clot will experience a DVT alone. However, DVT can progress to become a potentially fatal PE if the blood clot breaks apart and travels to the lungs, ultimately blocking a blood vessel there. Even in the absence of a PE, DVT alone can have devastating and costly consequences such as post-thrombotic syndrome and an increased risk of recurring blood clots, and thus the achievement of treatment goals is critically important. The current treatment standard for DVT is the dual- drug approach of low molecular weight heparin administered by subcutaneous injection, with a VKA.

About Xarelto® (Rivaroxaban)

Rivaroxaban is an oral anticoagulant that was discovered in Bayer HealthCare's Pharmaceuticals' Wuppertal laboratories in Germany, and is being jointly developed by Bayer HealthCare Pharmaceuticals and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. It has a rapid onset of action with a predictable dose response and high bioavailability, no requirement for routine coagulation monitoring, as well as a limited potential for food and drug interactions. Like other similar medicines (antithrombotic agents), rivaroxaban may cause bleeding which may potentially be life threatening.

Rivaroxaban is marketed under the brand name Xarelto® for VTE prevention in adult patients following elective hip or knee replacement surgery. Rivaroxaban is approved in more than 110 countries worldwide and to date has been successfully launched in more than 85 countries by Bayer HealthCare Pharmaceuticals in this indication. In the U.S., where rivaroxaban has been successfully launched in July 2011, Janssen Pharmaceuticals, Inc. (a Johnson & Johnson Company) holds marketing rights for rivaroxaban. The Bayer HealthCare Pharmaceuticals sales force is supporting the Janssen Pharmaceuticals, Inc. in designated hospital accounts.

The ROCKET AF study compared once daily
'/>"/>

SOURCE Bayer UK
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery
2. Surgex(TM) Becomes the First and Only BSCG (Banned Substance Control Group) Certified Product Which is Clinically Proven Effective in Sports Recovery and Performance
3. Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen-Deprivation Therapy
4. The Ocean Becomes a Pipeline To A Cure for Cystic Fibrosis
5. CTMM Becomes One of the Worlds Largest Public-Private Partnerships in Translational Medical Research
6. Fora Care Group Becomes Pioneering Educational Member of the International Society of Vascular Health
7. US Oncology Foundation Becomes Life Beyond Cancer Foundation
8. Sigma-Aldrich Becomes the Sole U.S. and Canada Distributor of Kromasil(R) HPLC Columns Through Agreement With Eka Chemicals
9. Triage Wireless, Inc. Becomes Sotera Wireless, Inc.
10. Brookstone Pharmaceuticals, LLC becomes Acella Pharmaceuticals, LLC
11. CVS Caremarks MinuteClinic Becomes First Retail Clinic Provider to Achieve Consecutive Accreditation Awards From The Joint Commission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014  Unilife Corporation ("Unilife" or "Company") ... that it intends to release its financial results for ... 30, 2014 after market trading ends on Tuesday, September ... conference call for 4:30 p.m. U.S. EDT on Tuesday, ... a.m. AEST), to review the Company,s financial results, commercial partnerships, ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Multiple Sclerosis Drugs Market 2014-2018" report to their ... inflammatory medical condition that results in demyelination, axonal transection, ... an abnormal response by the immune system, which targets ... a potentially debilitating disease in which the damage of ...
(Date:8/29/2014)... UNION CITY, Calif. , Aug. 29, 2014 /PRNewswire/ ... products company manufacturing point-of-care blood instrumentation and consumables to ... Clint Severson , Chairman and Chief Executive Officer, ... Annual Best Ideas Conference 2014 on Tuesday, September 9, ... held at the Omni Berkshire Place Hotel in ...
Breaking Medicine Technology:Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2
... Novavax, Inc. (Nasdaq: NVAX ) announced today ... its virus-like-particle (VLP) H1N1 influenza vaccine in Mexico in ... Avimex distributes biological and pharmaceutical products for use in ... world. Avimex is providing financial support for the ...
... , SHENYANG, China, Oct. 20 ... "Company"), a leading China-based biotechnology,company focused on researching, developing, ... its annual general,meeting of shareholders held on October 12, ... the Company,s shareholders re-elected Dr. Jing Lou and Mr.,Moujia ...
Cached Medicine Technology:Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico 2Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico 3Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico 4Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico 5
(Date:8/30/2014)... Dallas, TX (PRWEB) August 30, 2014 ... Cell Disruptor Industry, 2009-2019 is a professional and ... Disruptor industry. The report firstly reviews the basic ... and manufacturing technology. The report then explores global ... their product specification, capacity, Production value, and market ...
(Date:8/30/2014)... Hundreds of Byetta lawsuits ( http://www.byettalawsuit.com ... forward in U.S. courts, Bernstein Liebhard LLP reports. According ... 31, 2014, Byetta and Bydureon (an extended-release version of ... that allege the drugs caused pancreatitis, pancreatic cancer and ... claims are pending in a multidistrict litigation underway in ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 Continuing to ... Dermatology is expanding with the addition of a new ... Hammond who has provided leading-edge skin care in Grand ... Dermatology. , “As a doctor, my passion is ... Through partnering with Forefront Dermatology, I’m better able to ...
(Date:8/30/2014)... 2014 In today’s world, a good night’s ... Snoring and sleep apnea (a medical problem where the airway ... bed partners of the rest they need to face their ... snores and 20 million people in the United States alone ... and treated; and of those treated, many cannot tolerate their ...
(Date:8/30/2014)... "My wife suffered neck, back and spine ... one of two inventors from Bethel, Alaska. "The whiplash ... neck area. She tried other pillows to little avail. ... in comfort and providing extra sleep." , They created ... the head, neck and back comfortably. This enables the ...
Breaking Medicine News(10 mins):Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 3Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 4Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Expanding Care at the Forefront of Dermatology 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... To Follow Along Online, WICHITA, Kan., May 22 ... top of the world -- Mount Everest -- that ... Climb another,mountain? How about climb to the highest point ... in 50 days or less., (Photo: http://www.newscom.com/cgi-bin/prnh/20080522/AQTH080LOGO ...
... The 39th gathering of the Texas Annual,Conference of the ... to help celebrate the success of the Nothing But ... and,Cote d,Ivoire (Ivory Coast). The Woodlands UMC will host ... reading and signing on May 28 at 10:45 a.m., ...
... colleagues, at Weill Medical College of Cornell University, New York, ... shed doubt on the recently proposed designation of the protein ... a term given to the small number of cells within ... give rise to a new tumor and that therefore are ...
... rates or other outcomes was found between a group ... dialysis and another group that received a more standard ... Veterans Affairs (VA) and National Institutes of Health (NIH) ... England Journal of Medicine. Acute kidney injury, also called ...
... Corporation,(Nasdaq: CRGN ) announced today the completion ... the Company sold the 5,000,000 shares of,TopoTarget common ... for the,sale of CuraGen,s ownership in belinostat. After ... "We are pleased to announce the planned, ...
... for those seeking ... ... Board (PTCB) announced today that over 300,000 pharmacy,technicians have officially ... Pharmacy Technician,Certification Examination or transfer process since the program,s inception,in ...
Cached Medicine News:Health News:Denver Schoolteacher to Climb Summits of 50 States in 50 Days 2Health News:Denver Schoolteacher to Climb Summits of 50 States in 50 Days 3Health News:Local Methodists Host West African Choir, South African Leader at Historic Conference 2Health News:More intensive dialysis does not improve outcomes among patients with acute kidney injury 2Health News:CuraGen Sells 5 Million TopoTarget Shares for Approximately $12 Million 2Health News:CuraGen Sells 5 Million TopoTarget Shares for Approximately $12 Million 3Health News:Pharmacy Technician Certification Board (PTCB) Announces Milestone: 300,000 Certified Pharmacy Technicians (CPhT) 2Health News:Pharmacy Technician Certification Board (PTCB) Announces Milestone: 300,000 Certified Pharmacy Technicians (CPhT) 3
Stainless steel tray for sterilizing instruments....
For sterilizing, carrying and storage of a Storz diamond knife and barrel gauge....
Diamond knife tray with silicone inserts to securely hold the diamond knife....
Diamond knife tray with silicone inserts to securely hold the diamond knife....
Medicine Products: